PUBLICATION

Su Y, et al. Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVD-19. Cell (2020) DOI

We present an integrated analysis of the clinical measurements, immune cells, and plasma multi-omics of 139 COVID-19 patients representing all levels of disease severity, from serial blood draws collected during the first week of infection following diagnosis. We identify a major shift between mild and moderate disease, at which point elevated inflammatory signaling is accompanied by the loss of specific classes of metabolites and metabolic processes. Within this stressed plasma environment at moderate disease, multiple unusual immune cell phenotypes emerge and amplify with increasing disease severity. We condensed over 120,000 immune features into a single axis to capture how different immune cell classes coordinate in response to SARS-CoV-2. This immune-response axis independently aligns with the major plasma composition changes, with clinical metrics of blood clotting, and with the sharp transition between mild and moderate disease. This study suggests that moderate disease may provide the most effective setting for therapeutic intervention.

Keywords: immune response, multi-omics, COVID-19, infection, proteomics, metabolomics, single-cell TCR-seq, single-cell RNA-seq, CITE-seq, single-cell secretome

    Metabolon PUBLICATION

    Contact Us

    Talk with an expert

    Request a quote for our services, get more information on sample types and handling procedures, request a letter of support, or submit a question about how metabolomics can advance your research.

    Corporate Headquarters

    617 Davis Drive, Suite 100
    Morrisville, NC 27560

    Mailing Address:
    P.O. Box 110407
    Research Triangle Park, NC 27709

    +1 (919) 572-1711

    +1 (919) 572-1721

    International Headquarters

    Metabolon GmbH

    Zeppelinstraße 3
    85399 Hallbergmoos
    Germany